Study of Oligonucleotides Access and Distribution in Human Peripheral Blood Mononuclear Cells.
CD8+ Treg
FOXP3
PBMC
Treg
cell uptake
flow cytometry
fluorescent labeling
oligonucleotides
quenching
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
23 May 2022
23 May 2022
Historique:
received:
30
04
2022
revised:
17
05
2022
accepted:
19
05
2022
entrez:
28
5
2022
pubmed:
29
5
2022
medline:
1
6
2022
Statut:
epublish
Résumé
Therapeutic oligonucleotides have achieved great clinical interest since their approval as drug agents by regulatory agencies but their access and distribution in blood cells are not completely known. We evaluated by flow cytometry the ability of short fluorescent scramble oligonucleotides (ON*) to access human peripheral blood mononuclear cells (PBMC) after incubating with ON* during 1 h and 7 days of culture follow-up 'in vitro'. Blood samples were treated with chemically modified oligonucleotides (phosphorothioate backbone and 2' O-Me ends) to resist nuclease digestion under culture conditions. The ON* internalization was determined after discarding the membrane-associated fluorescence by trypan blue quenching. Whereas the oligonucleotide accessed neutrophils and monocytes rapidly, achieving their maximum in 1 h and 24 h, respectively, lymphocytes required 7 days to achieve the maximum (80% of cells) transfection. The ON*ability to access lymphocyte types (T, B, and NK) and T cell subtypes (CD4+, CD8+, and CD4-CD8-) were similar, with T cells being more accessible. Regulatory CD4+ and CD8+ T cells were classified in low and high Foxp3 expressers, whose expression proved not to alter the ON* internalization during the first hour, achieving 53% of CD4+Foxp3+ and 40% of CD8+Foxp3+ cells. Our results contribute to understanding and improving the management of therapeutic ONs.
Identifiants
pubmed: 35628649
pii: ijms23105839
doi: 10.3390/ijms23105839
pmc: PMC9143973
pii:
doi:
Substances chimiques
Forkhead Transcription Factors
0
Oligonucleotides
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Asociación Pablo Ugarte
ID : 2017/0561
Organisme : Agencia Valenciana de Innovación, Generalitat Valenciana
ID : 2021-066-01
Références
Cancer Biother Radiopharm. 1997 Oct;12(5):317-31
pubmed: 10851482
Drugs. 2021 May;81(7):875-879
pubmed: 33861387
Pharmaceutics. 2021 Nov 26;13(12):
pubmed: 34959297
Antioxidants (Basel). 2019 May 14;8(5):
pubmed: 31091728
J Immunol Methods. 1983 Feb 25;57(1-3):373-9
pubmed: 6402550
Vaccines (Basel). 2019 Nov 13;7(4):
pubmed: 31766202
ACS Cent Sci. 2019 May 22;5(5):882-891
pubmed: 31139724
Nat Rev Immunol. 2019 Nov;19(11):665-674
pubmed: 31570879
Nucleic Acids Res. 2010 Jan;38(1):e3
pubmed: 19854938
Biomolecules. 2020 Feb 17;10(2):
pubmed: 32079263
Wiley Interdiscip Rev RNA. 2020 Sep;11(5):e1594
pubmed: 32233021
Sci Rep. 2018 Oct 26;8(1):15841
pubmed: 30367171
Expert Opin Drug Metab Toxicol. 2021 Nov;17(11):1281-1292
pubmed: 34643122
Cytometry A. 2004 Apr;58(2):201-6
pubmed: 15057974
Nat Rev Drug Discov. 2021 Jun;20(6):427-453
pubmed: 33762737
J Hematother. 1995 Jun;4(3):149-58
pubmed: 7551914
Cytotechnology. 2009 Mar;59(2):103-11
pubmed: 19496017
Methods Mol Biol. 2019;2036:173-186
pubmed: 31410797
Nucleic Acids Res. 2019 May 21;47(9):4375-4392
pubmed: 30927008
Cytometry A. 2005 Jun;65(2):93-102
pubmed: 15825183
Science. 2021 Dec 17;374(6574):abe6474
pubmed: 34914499
Annu Rev Pharmacol Toxicol. 2017 Jan 6;57:81-105
pubmed: 27732800
Annu Rev Med. 2019 Jan 27;70:307-321
pubmed: 30691367
Cytometry. 1994 Dec 1;17(4):294-301
pubmed: 7875036
Front Immunol. 2020 Dec 08;11:580547
pubmed: 33363532
Nat Biotechnol. 2017 Mar;35(3):230-237
pubmed: 28244996
Int J Mol Sci. 2021 Mar 24;22(7):
pubmed: 33804856
Onco Targets Ther. 2017 Jan 23;10:503-514
pubmed: 28176947
Int J Mol Sci. 2021 Mar 27;22(7):
pubmed: 33801683